Article
Oncology
Sizhi Paul Gao, Amber J. Kiliti, Kai Zhang, Naresh Vasani, Ninghui Mao, Emmet Jordan, Hannah C. Wise, Tripti Shrestha Bhattarai, Wenhuo Hu, Madeline Dorso, James A. Rodrigues, Kwanghee Kim, Aphrothiti J. Hanrahan, Pedram Razavi, Brett Carver, Sarat Chandarlapaty, Jorge S. Reis-Filho, Barry S. Taylor, David B. Solit
Summary: The activation of AKT1 E17K mutation enhances cell growth and colony formation, but inhibits cell migration and invasion by increasing E-cadherin expression. This paradoxical effect may have implications for the use of AKT inhibitors in breast cancer patients with specific genetic backgrounds.
MOLECULAR CANCER RESEARCH
(2021)
Article
Materials Science, Multidisciplinary
Xiaoqing Li, Fanghui Ma, Minghui Yang, Jianglin Zhang
Summary: Female breast cancer is a major global health issue, with high incidence and mortality rates. Detecting biomarkers in the blood using nanomaterials has shown promising results and offers a noninvasive approach that complements traditional imaging and immunohistochemistry methods.
MATERIALS TODAY ADVANCES
(2022)
Article
Cell Biology
Bijesh George, Bin Gui, Rajeswari Raguraman, Aswathy Mary Paul, Harikrishna Nakshatri, Madhavan Radhakrishna Pillai, Rakesh Kumar
Summary: This study reveals the impact of AKT1-specific transcriptomic changes on breast cancer cells and identifies the cellular functions of AKT1. The study unexpectedly discovers the inherent role of AKT1 in inhibiting the expression of certain genes in breast cancer cells. The findings provide a resource for further understanding of AKT1-dependent modulation of gene expression in breast cancer cells.
Article
Oncology
Tatsunori Shimoi, Jun Hashimoto, Kazuki Sudo, Akihiko Shimomura, Emi Noguchi, Chikako Shimizu, Mayu Yunokawa, Kan Yonemori, Hiroshi Yoshida, Masayuki Yoshida, Tomoyasu Kato, Takayuki Kinoshita, Takahiro Fukuda, Yasuhiro Fujiwara, Kenji Tamura
Summary: The frequency of AKT1 mutations in Asian women with breast cancer and endometrial cancer is relatively low, at 7.4% and 4.1% respectively. AKT1 mutations are more common in HER2-negative breast cancer subtypes and in endometrial cancer with endometrioid histology. The frequencies of AKT1 mutations were similar between Asian and other regional women, and the predictive significance of these mutations in both tumor types is limited due to their low frequency.
Article
Oncology
Kevin Kalinsky, Fangxin Hong, Carolyn K. McCourt, Jasgit C. Sachdev, Edith P. Mitchell, James A. Zwiebel, L. Austin Doyle, Lisa M. McShane, Shuli Li, Robert J. Gray, Larry V. Rubinstein, David Patton, Paul M. Williams, Stanley R. Hamilton, Barbara A. Conley, Peter J. O'Dwyer, Lyndsay N. Harris, Carlos L. Arteaga, Alice P. Chen, Keith T. Flaherty
Summary: This study demonstrates that a clinically significant objective response rate was achieved in patients with an AKT1 E17K-mutated tumor treated with the pan-AKT inhibitor capivasertib, including one complete response.
Review
Chemistry, Analytical
Ali Mohammadpour-Haratbar, Seyyed Behnam Abdollahi Boraei, Yasser Zare, Kyong Yop Rhee, Soo-Jin Park
Summary: Breast cancer is the second most common cancer in the world, and various biosensor strategies, including electrochemical biosensors, have been studied for its recognition. Graphene-based electrochemical biosensors have received increasing attention due to their outstanding mechanical and electrical performances. This review examines the latest advances in graphene-based electrochemical biosensors for breast cancer biosensing, analyzing the detection limit, linear range, and diagnosis techniques for each biosensor, discussing prospects, challenges, and potential strategies for enhancing their performance.
Article
Mathematics, Interdisciplinary Applications
Annie Julie Joseph, P. N. Pournami
Summary: This study investigates various phases of mammogram image analysis and different abnormality detection techniques using Multifractal theory. The findings suggest that multifractal parameters could serve as valuable biomarkers for quantitative assessment of breast tissue in mammograms, aiding in the early diagnosis of breast cancer.
CHAOS SOLITONS & FRACTALS
(2021)
Article
Oncology
Debbie Lee Bennett, Andrea Marie Winter, Laura Billadello, Mary Catherine Lowdermilk, Christina Michelle Doherty, Sakina Kazmi, Sydney Laster, Noor Al-Hammadi, Anna Hardy, Daniel B. Kopans, Linda Moy
Summary: This study aimed to determine the feasibility of collecting method of detection (MOD) in a multicenter community registry and to compare outcomes and characteristics of breast cancer based on MOD in the United States. The results showed significant differences in outcome and characteristics of breast cancers based on MOD, and suggested that routine inclusion of MOD in US tumor registries would help quantify the impact of opportunistic screening mammography.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Biochemistry & Molecular Biology
Ambritha Balasundaram, S. Udhaya Kumar, D. Thirumal Kumar, Aditi Anil Dedge, R. Gnanasambandan, K. Satish Srinivas, R. Siva, C. George Priya Doss
Summary: Circulating free DNA (cfDNA) analysis can detect specific genetic abnormalities in female breast cancer patients, which enables targeted therapy selection, prognosis, and treatment effectiveness monitoring. This study used various methods to determine the pathogenicity of observed mutations and investigate the functional significance of the SMAD4 V465M mutation through molecular dynamics (MD) simulation analysis. The results suggest a significant association between the SMAD4 V465M mutation and breast cancer.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2023)
Article
Spectroscopy
H. F. Nargis, H. Nawaz, H. N. Bhatti, K. Jilani, M. Saleem
Summary: This study utilized SERS and RS for the classification of breast cancer patients and healthy individuals based on serum samples, finding that SERS showed higher sensitivity, specificity, and AUROC values compared to RS in distinguishing breast cancer from healthy samples. The study demonstrated the potential of SERS as a more effective analytical tool for understanding the progression of breast cancer.
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
(2021)
Article
Oncology
Vasily Giannakeas, David W. Lim, Steven A. Narod
Summary: Women with unilateral breast cancer have an annual risk of contralateral breast cancer similar to 0.4% per year, which persists over the 25-year follow-up period. The 25-year cumulative risk of contralateral invasive breast cancer was 9.9%, with variations based on age of diagnosis, time since diagnosis, race, and ER status of the first cancer.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Yoko Hashimoto, Nanae Masunaga, Naofumi Kagara, Kaori Abe, Tetsuhiro Yoshinami, Masami Tsukabe, Yoshiaki Sota, Tomohiro Miyake, Tomonori Tanei, Masafumi Shimoda, Kenzo Shimazu
Summary: A highly sensitive mutation detection method called LNA-clamp ddPCR was developed and validated in this study. By using this method, it was found that 12.7% of patients with primary breast cancer had ESR1 mutations, with Y537S and D538G being the most common mutations. The study also demonstrated the presence of minor clones with a VAF of <0.1%.
Article
Oncology
Kosmas Kepesidis, Masa Bozic-Iven, Marinus Huber, Nashwa Abdel-Aziz, Sharif Kullab, Ahmed Abdelwarith, Abdulrahman Al Diab, Mohammed Al Ghamdi, Muath Abu Hilal, Mohun R. K. Bahadoor, Abhishake Sharma, Farida Dabouz, Maria Arafah, Abdallah M. Azzeer, Ferenc Krausz, Khalid Alsaleh, Mihaela Zigman, Jean-Marc Nabholtz
Summary: In this study, FTIR spectroscopy was evaluated as a potential method for breast cancer detection by analyzing blood plasma. The results showed promising performance with an average AUC of 0.79 in 10-fold cross-validation, supporting the potential of using blood-based infrared probing for early breast cancer detection.
Article
Biochemistry & Molecular Biology
Byungkyu Park, Jinho Im, Kyungsook Han
Summary: Breast cancer is a common and deadly cancer among females. Basal-like breast cancer, one of its subtypes, has the lowest survival rate with no effective treatments available. This study aimed to identify gene correlations and potential prognostic gene pairs for breast cancer patients. Comparative analysis revealed several new gene pairs with opposing correlations and prognostic genes for patients with a wild-type TP53 gene. Findings from this study provide important insights for prognosis and drug target selection in breast cancer, especially in basal-like breast cancer.
Article
Chemistry, Analytical
Madallah Alruwaili, Walaa Gouda
Summary: This study proposes a framework based on transfer learning, utilizing various data augmentation strategies and pre-trained classification networks to distinguish between malignant and benign breast cancer. The system demonstrates high accuracy in experiments, highlighting its feasibility in medical imaging.
Article
Biochemical Research Methods
Alice C. O'Farrell, Ian S. Miller, Rhys Evans, Marina Alamanou, Maurice Cary, Girish Mallya Udupi, Adam Lafferty, Naser Monsefi, Mattia Cremona, Jochen H. M. Prehn, Henk M. Verheul, William M. Gallagher, Mathias Gehrmann, Annette T. Byrne
PROTEOMICS CLINICAL APPLICATIONS
(2019)
Article
Endocrinology & Metabolism
Anne-Marie Baird, David Easty, Monika Jarzabek, Liam Shiels, Alex Soltermann, Sonja Klebe, Stephane Raeppel, Lauren MacDonagh, Chengguang Wu, Kim Griggs, Michaela B. Kirschner, Bryan Stanfill, Daisuke Nonaka, Chandra M. Goparaju, Bruno Murer, Dean A. Fennell, Dearbhaile M. O'Donnell, Martin P. Barr, Luciano Mutti, Glen Reid, Stephen Finn, Sinead Cuffe, Harvey I. Pass, Isabelle Opitz, Annette T. Byrne, Kenneth J. O'Byrne, Steven G. Gray
FRONTIERS IN ENDOCRINOLOGY
(2019)
Article
Instruments & Instrumentation
Bo Lou, Kate Connor, Kieron Sweeney, Ian S. Miller, Alice O'Farrell, Eduardo Ruiz-Hernandez, David M. Murray, Garry P. Duffy, Alan Wolfe, Enrico Mastrobattista, Annette T. Byrne, Wim E. Hennink
DRUG DELIVERY AND TRANSLATIONAL RESEARCH
(2019)
Review
Gastroenterology & Hepatology
Wolf H. Fridman, Ian S. Miller, Catherine Sautes-Fridman, Annette T. Byrne
Article
Oncology
Franck Morschhauser, Jean-Pascal Machiels, Gilles Salles, Sylvie Rottey, Simon A. J. Rule, David Cunningham, Frederic Peyrade, Christophe Fruchart, Hendrik-Tobias Arkenau, Isabelle Genvresse, Li Liu, Karl Koechert, Kui Shen, Christoph Kneip, Carol E. Pena, Joachim Grevel, Jun Zhang, Galia Cisternas, Susanne Reschke, Camille Granvil, Ahmad Awada
MOLECULAR CANCER THERAPEUTICS
(2020)
Editorial Material
Gastroenterology & Hepatology
Rodrigo Dienstmann, Kate Connor, Annette T. Byrne
Article
Oncology
Janis J. Noonan, Monika Jarzabek, Frank A. Lincoln, Brenton L. Cavanagh, Arhona R. Pariag, Viktorija Juric, Leonie S. Young, Keith L. Ligon, Hanne Jahns, Daniella Zheleva, Jochen H. M. Prehn, Markus Rehm, Annette T. Byrne, Brona M. Murphy
Article
Multidisciplinary Sciences
Ana Barat, Dominiek Smeets, Bruce Moran, Wu Zhang, Shu Cao, Sudipto Das, Rut Klinger, Johannes Betge, Verena Murphy, Orna Bacon, Elaine W. Kay, Nicole C. T. Van Grieken, Henk M. W. Verheul, Timo Gaiser, Nadine Schulte, Matthias P. Ebert, Bozena Fender, Bryan T. Hennessy, Deborah A. McNamara, Darran O'Connor, William M. Gallagher, Chiara Cremolini, Fotios Loupakis, Aparna Parikh, Christoph Mancao, Bauke Ylstra, Diether Lambrechts, Heinz-Josef Lenz, Annette T. Byrne, Jochen H. M. Prehn
SCIENTIFIC REPORTS
(2020)
Review
Oncology
K. White, K. Connor, J. Clerkin, B. M. Murphy, M. Salvucci, A. C. O'Farrell, M. Rehm, D. O'Brien, J. H. M. Prehn, S. P. Niclou, M. L. M. Lamfers, M. Verreault, A. Idbaih, R. Verhaak, A. Golebiewska, A. T. Byrne
ANNALS OF ONCOLOGY
(2020)
Article
Oncology
Alice C. O'Farrell, Monika A. Jarzabek, Andreas U. Lindner, Steven Carberry, Emer Conroy, Ian S. Miller, Kate Connor, Liam Shiels, Eugenia R. Zanella, Federico Lucantoni, Adam Lafferty, Kieron White, Mariangela Meyer Villamandos, Patrick Dicker, William M. Gallagher, Simon A. Keek, Sebastian Sanduleanu, Philippe Lambin, Henry C. Woodruff, Andrea Bertotti, Livio Trusolino, Annette T. Byrne, Jochen H. M. Prehn
Article
Oncology
Kate Connor, David W. Murray, Monika A. Jarzabek, Nhan L. Tran, Kieron White, Patrick Dicker, Kieron J. Sweeney, Philip J. O'Halloran, Brian MacCarthy, Liam P. Shiels, Francesca Lodi, Diether Lambrechts, Jann N. Sarkaria, Raymond M. Schiffelers, Marc Symons, Annette T. Byrne
Article
Oncology
Kathrin D. Wurster, Mariantonia Costanza, Stephan Kreher, Selina Glaser, Bjoern Lamprecht, Nikolai Schleussner, Ioannis Anagnostopoulos, Michael Hummel, Korinna Joehrens, Harald Stein, Arturo Molina, Arjan Diepstra, Bernd Gillissen, Karl Koechert, Reiner Siebert, Olaf Merkel, Lukas Kenner, Martin Janz, Stephan Mathas
Summary: Anaplastic large cell lymphoma (ALCL) is a type of lymphoid malignancy derived from T cells, which can be divided into ALK(+) and ALK(-) categories. Despite genomic and molecular differences, both ALK(+) and ALK(-) ALCL share similarities in key biological and molecular features. Aberrant expression of CD74 in ALCL may provide insights for developing new treatment strategies.
Article
Oncology
Ian S. Miller, Sonja Khan, Liam P. Shiels, Sudipto Das, Alice C. O' Farrell, Kate Connor, Adam Lafferty, Bruce Moran, Claudio Isella, Paul Loadman, Emer Conroy, Susan Cohrs, Roger Schibli, Robert S. Kerbel, William M. Gallagher, Elisabetta Marangoni, Kathleen Bennett, Darran P. O' Connor, Roisin M. Dwyer, Annette T. Byrne
Summary: The study showed that aspirin could delay metastasis in HER2+ breast cancer and reduce the growth of primary tumors in HER2+/TNBC. However, no survival benefit was observed in aspirin pre-treated animals that also received standard of care chemotherapy. Aspirin altered breast tumor biology through various mechanisms but may not be an effective chemopreventive agent in HER2+ or TNBC setting.
Article
Oncology
Ioannis Ntafoulis, Anne Kleijn, Jie Ju, Kevin Jimenez-Cowell, Federica Fabro, Michelle Klein, Romain Tching Chi Yen, Rutger K. Balvers, Yunlei Li, Andrew P. Stubbs, Trisha V. Kers, Johan M. Kros, Sean E. Lawler, Laurens V. Beerepoot, Andreas Kremer, Ahmed Idbaih, Maite Verreault, Annette T. Byrne, Alice C. O'Farrell, Kate Connor, Archita Biswas, Manuela Salvucci, Jochen H. M. Prehn, Diether Lambrechts, Gonca Dilcan, Francesca Lodi, Ingrid Arijs, Martin J. van den Bent, Clemens M. F. Dirven, Sieger Leenstra, Martine L. M. Lamfers
Summary: This study found that patient-derived glioma stem-like cells (GSCs) retain patient-unique gene expressions despite the loss of their natural environment. Drug screening using GSCs predicted patient response to temozolomide (TMZ) more specifically than the MGMT status alone. Transcriptome analysis identified potential biomarkers for TMZ sensitivity.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Giuseppe Gullo, Alex J. Eustace, Alexandra Canonici, Denis M. Collins, Michael J. Kennedy, Liam Grogan, Oscar Breathhnach, John McCaffrey, Maccon Keane, Michael J. Martin, Rajnish Gupta, Gregory Leonard, Miriam O'Connor, Paula M. Calvert, Paul Donnellan, Janice Walshe, Enda McDermott, Kathleen Scott, Andres Hernando, Imelda Parker, David W. Murray, Alice C. O'Farrell, Ashwini Maratha, Patrick Dicker, Mairin Rafferty, Verena Murphy, Norma O'Donovan, William M. Gallagher, Bonnie Ky, Dimitrios Tryfonopoulos, Brian Moulton, Annette T. Byrne, John Crown
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2019)